Serotonin and melatonin secretion and metabolism in patients with liver cirrhosis

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue 9, 2012, Pages 392-397

  Chojnacki, Cezary ^a   Walecka Kapica, Ewa ^a   Klupińska, Grazyna ^a   Wachowska Kelly, Patrycja ^a   Zylińska, Krystyna ^a   Winczyk, Katarzyna ^a   Chojnacki, Jan ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

5 hydroxyindoleacetic acid; 6 sulfatoxymelatonin; Liver cirrhosis; Melatonin; Serotonin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 6 HYDROXYMELATONIN O SULFATE; MELATONIN; SEROTONIN;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CHILD PUGH CLASSIFICATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HORMONE BLOOD LEVEL; HUMAN; LIVER FAILURE; MAJOR CLINICAL STUDY; MELATONIN BLOOD LEVEL; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; SEROTONIN BLOOD LEVEL; URINARY EXCRETION;

EID: 84868670349     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1371     Document Type: Article

References (46)

1. Walther DJ, Peter JU, Bashammakh S, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science. 2003; 299: 76. (Pubitemid 36042402)
2. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007; 132: 397-414. (Pubitemid 46127672)
3. Bertrand PP. Real-time detection of serotonin release from enterochromaffin cells of the guinea-pig ileum. Neurogastroenterol Motil. 2004; 16: 511-514. (Pubitemid 39472184)
4. Brenner B, Harney JT, Ahmed BA, et al. Plasma serotonin levels and the platelet serotonin transporter. J Neurochem. 2007; 102: 206-215. (Pubitemid 46906271)
5. Gershon MD. Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther. 2004; 20: 3-14. (Pubitemid 39657670)
6. Joy T, Walsh G, Tokmakejian S, Van Uum SH. Increase of urinary 5-hydroxyindoleacetic acid excretion but not serum chromogranin A following over-the-counter 5 hydroxytryptophan intake. Can J Gastroenterol. 2008; 22: 49-53. (Pubitemid 351385652)
7. Reiter RJ, Tan DX. What constitutes a physiological concentration of melatonin? J Pineal Res. 2003; 34: 79-80. (Pubitemid 36140362)
8. Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci. 2002; 47: 2336-2348. (Pubitemid 35205309)
9. Kvetnoy IM, Ingel IE, Kvetnaia TV, et al. Gastrointestinal melatonin: cellular identification and biological role. Neuro Endocrinol Lett. 2002; 23: 121-132. (Pubitemid 34495405)
10. Reiter RJ, Tan DX, Mayo JC, et al. Neurally-mediated and neurally-independent beneficial actions of melatonin in the gastrointestinal tract. J Physiol Pharmacol. 2003; 54 (Suppl 4): 113-125.
11. Gibson P, Gill JH, Khan PA, et al. Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol Cancer Ther. 2003; 2: 527-534.
12. Lane EA, Moss HB. Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab. 1985; 61: 1214-1216. (Pubitemid 16186729)
13. Facciolá G, Hidestrand M, von Bahr C. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol. 2001; 56: 881-888. (Pubitemid 33788564)
14. Ma X, Idle JR, Krausz KW, Gonzalez FJ. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005; 33: 489-494. (Pubitemid 40393190)
15. Tan D, Manchester LC, Reiter RJ, et al. High physiological levels of melatonin in the bile of mammals. Life Sci. 1999; 65: 2523-2529.
16. Messner M, Huether G, Lorf T, et al. Presence of melatonin in the human hepatobiliary-gastrointestinal tract. Life Sci. 2001; 69: 543-551. (Pubitemid 32601981)
17. Letelier ME, Jara-Sandoval J, Molina-Berríos A, et al. Melatonin protects the cytochrome P450 system through a novel antioxidant mechanism. Chem Biol Interact. 2010; 185: 208-214.
18. Sahna E, Parlakpinar H, Vardi N, et al. Efficacy of melatonin as protectant against oxidative stress and structural changes in liver tissue in pinealectomized rats. Acta Histochem. 2004; 106: 331-336. (Pubitemid 39458117)
19. Mathes AM. Hepatoprotective actions of melatonin: possible mediation by melatonin receptors. World J Gastroenterol. 2010; 16: 6087-6097.
20. Cools R, Roberts AC, Robbins TW. Serotoninergic regulation of emotional and behavioural control processes. Trends Cogn Sci. 2008; 12: 31-40. (Pubitemid 50012215)
21. Yurdaydin C, Herneth AM, Püspök A, et al. Modulation of hepatic encephalopathy in rats with thioacetamide-induced acute liver failure by serotonin antagonists. Eur J Gastroenterol Hepatol. 1996; 8: 667-671. (Pubitemid 26241596)
22. Celinski K, Konturek PC, Slomka M, et al. Altered basal and postprandial plasma melatonin, gastrin, ghrelin, leptin and insulin in patients with liver cirrhosis and portal hypertension without and with oral administration of melatonin or tryptophan. J Pineal Res. 2009; 46: 408-414.
23. Ardizzi A, Grugni G, Saglietti G, Morabito F. [Circadian rhythm of melatonin in liver cirrhosis]. Minerva Med. 1998; 89: 1-4. Italian.
24. Montagnese S, Middleton B, Mani AR, et al. On the origin and the consequences of circadian abnormalities in patients with cirrhosis. Am J Gastroenterol. 2010; 105: 1773-1781.
25. Córdoba J, Cabrera J, Lataif L, et al. High prevalence of sleep disturbance in cirrhosis. Hepatology. 1998; 27: 339-245.
26. Steindl PE, Ferenci P, Marktl W. Impaired hepatic catabolism of melatonin in cirrhosis. Ann Intern Med. 1997; 127: 494. (Pubitemid 27400918)
27. Zee PC, Mehta R, Turek FW, Blei AT. Portacaval anastomosis disrupts circadian locomotor activity and pineal melatonin rhythms in rats. Brain Res. 1991; 560: 17-22.
28. Coy DL, Mehta R, Zee P. Portal-systemic shunting and the disruption of circadian locomotor activity in the rat. Gastroenterology. 1992; 103: 222-228.
29. Finn B, Shah V, Gottstein J. Neomycin improves a disrupted circadian rhythm in rats after portacaval anastomosis. Hepatogastroenterolgy. 1993; A-33.
30. Ducis J. Effect of ammonia and R05-4864 on melatonin release in pineal. J. Neurochem. 1994: 62: A-37.
31. Steindl PE, Finn B, Bendok B, et al. Disruption of the diurnal rhythm of plasma melatonin in cirrhosis. Ann Intern Med. 1995; 123: 274-277.
32. Suman A, Barnes DS, Zein NN, et al. Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child-Pugh and MELD scores. Clin Gastroenterol Hepatol. 2004; 2: 719-723. (Pubitemid 39013433)
33. Montagnese S, Amodio P, Morgan MY. Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach. Metab Brain Dis. 2004; 19: 281-312. (Pubitemid 39361189)
34. Ferenci P, Lockwood A, Mullen K. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002; 35: 716-721. (Pubitemid 34183979)
35. Butterworth RF. The neurobiology of hepatic encephalopathy. Semin Liver Dis. 1996; 16: 235-244. (Pubitemid 27029873)
36. Weissenborn K, Ennen JC, Schomerus H, et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol. 2001; 34: 768-773. (Pubitemid 32488796)
37. Ortiz M, Córdoba J, Jacas C, et al. Neuropsychological abnormalities in cirrhosis include learning impairment. J Hepatol. 2006; 44: 104-110. (Pubitemid 41772523)
38. De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut. 2004; 53: 1520-1535. (Pubitemid 39272827)
39. Bonaventure P, Nepomuceno D, Miller K, et al. Molecular and pharmacological characterization of serotonin 5-HT2A and 5-HT2B receptor subtypes in dog. Eur J Pharmacol. 2005; 513: 181-192. (Pubitemid 40616062)
40. Miura H, Ozaki N, Sawada M, et al. A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. Stress. 2008; 11: 198-209. (Pubitemid 351874183)
41. Christmas DM, Potokar J, Davies SJ. A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase. Neuropsychiatr Dis Treat. 2011; 7: 431-439.
42. Dantzer R, O'Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology. 2011; 36: 426-436.
43. Stone TW, Mackay GM, Forrest CM, et al. Tryptophan metabolites and brain disorders. Clin Chem Lab Med. 2003; 41: 852-859. (Pubitemid 37010175)
44. Stone TW, Forrest CM, Mackay GM, et al. Tryptophan, adenosine, neurodegeneration and neuroprotection. Metab Brain Dis. 2007; 22: 337-352. (Pubitemid 47624316)
45. Cichoz-Lach H, Celinski K, Konturek PC, et al. The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis. J Physiol Pharmacol. 2010; 61: 577-580.
46. Gonciarz M, Gonciarz Z, Bielanski W, et al. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin. J Physiol Pharmacol. 2010; 61: 705-710.